Governance

Our Board of Directors comprises key industry players who are recognized for their expertise and come from biotech, big pharma, universities and the agri-tech sector, as well as representatives from Luxembourg Province and the Walloon Region!

Administrators on the Board of Directors of the CER Groupe

• BONTEMPS Philippe, Province du Luxembourg - Vice-President
• VANLOOCKE Olivier, CER Groupe - Administrator-Director
• BARET Philippe, UCL - Administrator
• BOUREZ Sophie, Wagralim - Administrator
• CASTILLO José, Univercells - Administrator
• DE BORMAN Béatrice, DIAsource ImmunoAssays - Administrator
• DENOEL Philippe, GSK Vaccines - Administrator
• GILLARD Dominique, Province du Luxembourg - Administrator
• GLATT Sophie, UCB - Administrator
• GRAVY Sophie, plusOne - Administrator
• MASSARD Christian, Province du Luxembourg - Administrator
• MOREAUX Benoit, 4Tissue & 2Bridge - President
• SMETS Katelijne, ARSIA - Administrator
• VINCENT Stéphane, UNamur - Administrator

Observers on the Board of Directors of the CER Groupe

• BASTIAENS Annette, Walloon Region - Observer
• VOLCKE Cédric, Walloon Region - Observer
• GORIELY Stanislas, ULB - Observer

Audit Committee

The Audit Committee assists the Board of Directors in its oversight and monitoring duties in the following areas:

• the correct application of accounting principles, as well as any changes that may be made to them in the light of changes in legislation;
• the quality and efficiency of the financial reporting process ;
• the analysis of the Foundation's budget, annual accounts and consolidated accounts, including inter-subsidiary transfers, as well as the annual management reports and the auditor's reports on this subject Analysis and follow-up of any significant adjustments to be made on the recommendation of the auditor in the context of the statutory audit;
• the analysis of any interim financial statements and any other financial communications to third parties;
• the analysis of all other important accounting, tax and financial reporting issues, including the reporting of complex and/or non-routine transactions.

Members of the Audit Committee:

• MORRO Terry - CFO West Europe Omaya
• VANDEBROEK Jean-Luc - CFO Hyloris

Strategic Committee

The roles of the Strategic Committee are:

To define a strategy and propose an implementation plan to the Board of Directors

To monitor the execution of the strategic plan by the Management Committee

To follow the evolution of the environnement and rectify the strategic plan if necessary

Members of the Strategic Committee:

• MOREAUX Benoit – President CA CER Groupe
• VANLOOCKE Olivier - CEO CER Groupe
• DENOËL Philippe – GSK
• GLATT Sophie – UCB
• WALLEMACK Hugues – Noshak
• DECHAMPS Marc – Investsud, Bioxodès
• LIZIN Pascal – SAMABRIVA
• DE BORMAN Beatrice – Diasource ImmunoAssays
• BOUREZ Sophie- Wagralim
• HEROUFOSSE François – INVENTIO
• SZPIRER Cédric - SlowSurg
• RENAULD Jean-Christophe - Universités